CER budgets heading up in '12

Share this article:

More than half of drug companies plan to increase spending for market-access activities in 2012, including comparative effectiveness research (CER), according to a report from Cutting Edge Information.

Responding to payer demands for outcomes, virtually all drug research companies expect to at least maintain spend across most market-access categories, the benchmarking study showed.

Growth areas include health economics and outcomes research (64% of firms plan to increase funding), as well as patient-reported-outcomes activities, pegged by 57% of respondents for more spend, and CER, which half of firms anticipate upping their spend for.

Across all market access activities studied, pricing teams' budgets will largely remain the same. And according to the study, 73% of companies will hold their pricing budgets steady next year.

Cutting Edge talked to 20 companies for its study, said Elio Evangelista, director of research for the firm.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?